The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | CAR T-cells in myeloma: are they as promising as we think?
With the impressive results from initial trials using CAR T-cells, excitement surrounding this modality as a curative therapy was high. However, as explained here by Faith Davies MD, MRCP, MRCPath, FRCPath, from UAMS Myeloma Institute, Little Rock, AR, CAR T-cells are still far from a curative therapy for multiple myeloma. Dr Davies highlights the additional work required if these impressive response rates are to be maintained, with a number of important questions remaining. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
